Our pipeline is based on next-generation technology platforms that take clinically validated approaches and improve on them with unique features that enable us to develop drugs against promising targets. It contains a diversified portfolio of promising clinical and pre-clinical stage drug candidates that we believe will improve people’s lives across our key therapeutic areas.

In oncology, our pipeline includes three-clinical stage bispecific antibody programmes focused on next-generation immuno-oncology and a 2nd generation STING agonist in phase I.

In respiratory, we have a pipeline of approved products to treat asthma and COPD that will be delivered via our Softhaler® platform. We are also investigating innovative molecules for other indications.